A federal jury in Lafayette, La., ordered Takeda Pharmaceutical Co., based in Osaka, Japan, and its partner, Eli Lilly & Co, based in Indianapolis, Ind., to pay a combined $9 billion in punitive damages. The jury determined the drug makers hid cancer risks associated with their Actos diabetes medicine from the public. The drug has been linked to the development of bladder cancer. This was the first federal trial in this litigation. Co-lead counsels Paul J. Pennock of Weitz & Luxenberg PC and Richard J. Arsenault of Neblett Beard & Arsenault represented former Actos user Terrence Allen and his wife, Susan, in the lawsuit. The Plaintiffs also were represented by Mark Lanier of the Lanier Law Firm in Houston, Texas, who was the lead attorney during the trial. Mr. Allen developed bladder cancer after using Actos. The jury also awarded the Allens $1.5 million in compensatory damages. Of the punitive damages, Takeda was ordered to pay $6 billion, while Lilly will pay $3 billion.

“Thousands of people have bladder cancer as a result of the egregious conduct of these drug companies regarding Actos,” said Beasley Allen lawyer Andy Birchfield, who is head of the firm’s Mass Torts section. “As long as potential drug sales are wildly lucrative, companies will face the temptation to ignore or hide serious safety concerns. This verdict sends a clear message for companies to beware; there is accountability in the courts.” Birchfield was appointed to the Plaintiffs’ Steering Committee (PSC) by U.S. District Judge Rebecca Doherty, who is in charge of the Actos multidistrict litigation (MDL). This committee heads up the Actos MDL and he assisted in the preparations for the Allen trial.

Actos lawsuits filed in federal courts have been consolidated under Judge Doherty in U.S. District Court for the Western District of Louisiana. Lawsuits claim Takeda and Eli Lilly misrepresented and omitted information it held about Actos and “actively concealed its risks.” The lawsuits also claim Plaintiffs were not adequately warned about Actos risks and could have taken several safer alternative drugs had they known about the health risks posed by Actos.

Actos is prescribed to treat Type 2 diabetes. The U.S. Food and Drug Administration (FDA) began a review of Actos and cancer risk in September 2010, when the agency issued a safety announcement suggesting a potential risk with Actos. The FDA reported in its data summary that the risk of bladder cancer increased with increasing dose and duration of Actos use, reaching statistical significance after 24 months of exposure. The FDA later updated its safety label for Actos to state that the use of the drug for more than one year may be associated with an increased risk of bladder cancer. In June 2011, the FDA issued a warning for Actos.

Sources:

Bloomberg News
Reuters



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

$2.4 Billion Actos Bladder Cancer Settlement Explained

Beasley Allen principal Frank Woodson discusses the recent $2.4 billion Actos settlement on Ringler...
Takeda settles Actos bladder cancer lawsuits for $2.4 billion

$2.4 billion settlement agreement reached in Actos...

Takeda Pharmaceutical Co. has agreed to a $2.4 billion settlement to resolve bladder cancer claims tied...
Federal jury orders drugmakers to pay $9 billion for actos cancer risk

Actos verdict illustrates companies that co-promote...

A federal judge’s decision not to overturn a jury’s $9 billion verdict against Takeda Pharmaceutical...

Actos and its link to bladder cancer discussed by...

Actos, manufactured by Takeda Pharmaceuticals, was issued a warning by the FDA saying people who have...

Actos, TVM and Zohydro litigation discussed by Andy...

Beasley Allen attorneys Andy Birchfield and Leigh O'Dell discuss their progress on litigation involving...

Type 2 diabetes drugs may increase risk of pancreatic...

A commonly prescribed class of Type 2 diabetes drugs known as incretin mimetics may put users at risk...

Best for clients

Great firm. Supports the community. They want what is best for their clients.

—Jennifer